Horm Metab Res 1992; 24(5): 237-239
DOI: 10.1055/s-2007-1003301
Clinical

© Georg Thieme Verlag, Stuttgart · New York

SMS 201-995 and Thyroid Function in Acromegaly:

Acute, Intermediate and Long-Term EffectsS. E. Christensen1 , J. Weeke1 , A. Kaal1 , A. G. Harris2 , H. Ørskov3
  • 1Medical Department M (Endocrinology and Diabetes), Aarhus Kommunehospital, Aarhus, Denmark
  • 2Division Clinical Pharmacology, Cedars-Sinai Medical Center, Los Angeles, U. S. A.
  • 3Medical Research Laboratories, Institute of Experimental Clinical Research, University of Aarhus, Aarhus, Denmark
Weitere Informationen

Publikationsverlauf

1991

1991

Publikationsdatum:
14. März 2008 (online)

Summary

The acute (TRH-stimulation test), intermediate (0-6 days administration), and long-term (0-30 months administration) effects of SMS 201-995 (octreotide) treatment on thyroid function were studied.

Subcutaneous injection of 100 μg SMS 201-995 one hour before 200 μg TRH intravenously reduced serum TSH response area by more than 50% in 8 healthy volunteers.

After 3 days of continuous subcutaneous infusion (CSI) of SMS 201-95 in 9 acromegalic patients (100 μg/24 h) a slight but significant decrease in serum total triiodothyronine (TT3) and a concomitant increase in serum TSH were demonstrated, indicating an initial inhibitory effect on peripheral deiodination of thyroxine. After a further 3 days treatment serum T3 and TSH had returned to prevalues.

Six of the nine acromegalics were treated with SMS 201-995 (100-1500 μg/24 h) and admitted for diurnal hormone profiles on 13 occasions over 30 months. Apart from a barely significant increase in serum TSH, no changes in thyroid function were noted.

The study was especially designed to detect minute changes over time in thyroid hormones. The only long-term effect of SMS 201-995 was the barely significant clinically irrelevant increase in serum TSH, possibly caused by a slight inhibition of peripheral deiodination of thyroxine.